Zai Lab Stock Forecast, Price & News

-1.23 (-0.75 %)
(As of 04/15/2021 12:00 AM ET)
Today's Range
Now: $163.60
50-Day Range
MA: $137.57
52-Week Range
Now: $163.60
Volume261,657 shs
Average Volume445,398 shs
Market Capitalization$14.49 billion
P/E RatioN/A
Dividend YieldN/A
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops, and commercializes therapeutics to treat oncology, autoimmune, and infectious diseases in China. The company offers ZEJULA for the treatment of breast cancer and non-small cell lung cancer (NSCLC); and Optune, a cancer therapy to treat glioblastoma multiforme. It also develops QINLOCK for the treatment of gastrointestinal stromal tumors; Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Bemarituzumab for the treatment of gastric and gastroesophageal junction cancer; and Omadacycline to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Efgartigimod to reduce disease-causing immunoglobulin G (IgG) antibodies; Retifanlimab to treat microsatellite instability high endometrial cancer; ZL-2309 for the treatment of metastatic pancreatic cancer, metastatic colorectal cancer, and other advanced solid tumors; ZL-1201 to treat solid tumors and hematological malignancies; ZL-1102 for the treatment of psoriasis; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited has license and collaboration agreements with the GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Zai Lab logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ZLAB
Year FoundedN/A



Sales & Book Value

Annual Sales$12.98 million
Book Value$5.07 per share



Market Cap$14.49 billion
Next Earnings DateN/A


Is ZLAB Stock A Buy or Sell?
April 14, 2021 |
Zai Lab (NASDAQ:ZLAB) PT Raised to $192.00 at SVB Leerink
April 14, 2021 |
Zai Lab (NASDAQ:ZLAB) Price Target Raised to $250.00
April 13, 2021 |
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $132.05
April 13, 2021 |
Zai Lab Limited (NASDAQ:ZLAB) CEO Sells $2,948,637.12 in Stock
April 7, 2021 |
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $127.69
April 7, 2021 |
First Week of ZLAB May 21st Options Trading
March 22, 2021 |
Zai Lab is Now Oversold (ZLAB)
March 8, 2021 |
Zai Lab Reaches Analyst Target Price
March 2, 2021 |
Zai Lab earnings: here's what to expect
February 28, 2021 |
ZLAB Mar 2021 165.000 call
February 19, 2021 |
See More Headlines


Overall MarketRank

1.42 out of 5 stars

Medical Sector

626th out of 2,021 stocks

Pharmaceutical Preparations Industry

290th out of 772 stocks

Analyst Opinion: 2.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-1.23 (-0.75 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

Is Zai Lab a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab
or view top-rated stocks.

What stocks does MarketBeat like better than Zai Lab?

Wall Street analysts have given Zai Lab a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zai Lab wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Zai Lab?

Zai Lab saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,920,000 shares, an increase of 31.5% from the February 28th total of 1,460,000 shares. Based on an average daily volume of 389,900 shares, the days-to-cover ratio is presently 4.9 days.
View Zai Lab's Short Interest

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) posted its quarterly earnings data on Thursday, March, 19th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.05. The company had revenue of $4.65 million for the quarter.
View Zai Lab's earnings history

How has Zai Lab's stock been impacted by COVID-19?

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZLAB stock has increased by 226.4% and is now trading at $163.60.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ZLAB?

5 equities research analysts have issued twelve-month price targets for Zai Lab's stock. Their forecasts range from $111.00 to $250.00. On average, they anticipate Zai Lab's stock price to reach $197.85 in the next year. This suggests a possible upside of 20.9% from the stock's current price.
View analysts' price targets for Zai Lab
or view top-rated stocks among Wall Street analysts.

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:
  • Dr. Ying Du, Founder, Chairperson & CEO (Age 55)
  • Mr. Tao Fu, Pres, COO & Director (Age 49)
  • Mr. Ki Chul Cho, Chief Financial Officer (Age 43)
  • Dr. Harald Reinhart M.D., Chief Medical Officer of Autoimmune & Infectious Diseases (Age 69)
  • Mr. Yi Liang M.B.A., M.D., Chief Commercial Officer & Pres of Greater China (Age 50)
  • Mr. Frazor Titus Edmondson III, Chief Legal Officer
  • Ms. Ann Beasley, Chief Compliance Officer
  • Dr. Ning Xu M.D., Exec. VP & Head of Clinical Operations (Age 56)
  • Dr. Jonathan J. Wang M.B.A., Ph.D., MBA, Sr. VP & Head of Bus. Devel. (Age 39)
  • Dr. James Yan DABT, M.D., Ph.D., Chief Operating Officer of R&D (Age 57)

Who are some of Zai Lab's key competitors?

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), (JD), Bilibili (BILI), Marvell Technology Group (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by many different retail and institutional investors. Top institutional investors include E Fund Management Hong Kong Co. Ltd. (0.02%), Redpoint Investment Management Pty Ltd (0.01%), Calamos Advisors LLC (0.00%), Golden Green Inc. (0.00%) and Crossmark Global Holdings Inc. (0.00%). Company insiders that own Zai Lab stock include Kai-Xian Chen and Ying Du.
View institutional ownership trends for Zai Lab

Which institutional investors are selling Zai Lab stock?

ZLAB stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC. Company insiders that have sold Zai Lab company stock in the last year include Kai-Xian Chen, and Ying Du.
View insider buying and selling activity for Zai Lab
or view top insider-selling stocks.

Which institutional investors are buying Zai Lab stock?

ZLAB stock was acquired by a variety of institutional investors in the last quarter, including Redpoint Investment Management Pty Ltd, Golden Green Inc., Crossmark Global Holdings Inc., and E Fund Management Hong Kong Co. Ltd..
View insider buying and selling activity for Zai Lab
or or view top insider-buying stocks.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $163.60.

How much money does Zai Lab make?

Zai Lab has a market capitalization of $14.49 billion and generates $12.98 million in revenue each year. The company earns $-195,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.

How many employees does Zai Lab have?

Zai Lab employs 1,194 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is

Where are Zai Lab's headquarters?

Zai Lab is headquartered at 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]

This page was last updated on 4/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.